Kymera Therapeutics (KYMR) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 97.1% versus a loss of 3.3%. Over five years, KYMR leads with a +91.1% price change compared with -14.8% for QGEN. Qiagen N.V. is the larger company by market cap ($9.37 billion vs $9.25 billion), about 1.0 times the size.
Qiagen N.V. pays a dividend yielding 0.80%, while Kymera Therapeutics does not currently pay one. Qiagen N.V. converts more of its revenue into profit, with a net margin of 20.3% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | QGEN |
|---|---|---|
| Share price | $112.40 | $45.38 |
| Market cap | $9.25B | $9.37B |
| 1-day change | +2.84% | +1.91% |
| YTD return | +44.45% | +0.91% |
| 1-year return | +97.12% | -3.30% |
| 5-year return | +91.08% | -14.85% |
| P/E ratio (TTM) | — | 22.69 |
| Forward P/E | — | 17.37 |
| EPS (TTM) | $-3.34 | $2.00 |
| Dividend yield | 0.00% | 0.80% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | $39.21M | $2.09B |
| Revenue growth (YoY) | -16.70% | +5.65% |
| Net income (latest FY) | $-311.35M | $424.88M |
| Gross margin | 0.00% | 62.18% |
| Operating margin | -891.07% | 22.29% |
| Net margin | -794.04% | 20.33% |
| 52-week high | $130.05 | $57.82 |
| 52-week low | $55.26 | $32.53 |
| Distance from 52-week high | -13.57% | -21.52% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.95% | +4.16% |
| Average volume | 705.63K | 2.56M |
| Shares outstanding | 82.26M | 206.50M |
| Employees | 273 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed QGEN by 100.4 percentage points over the past year.
- Qiagen N.V. is more profitable, keeping 20.3 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Qiagen N.V. grew revenue faster in its latest fiscal year (+5.65% vs -16.70%).
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
KYMR vs QGEN FAQ
Which is bigger, Kymera Therapeutics or Qiagen N.V.?
Qiagen N.V. (QGEN) is larger, with a market capitalization of $9.37B compared with $9.25B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or QGEN?
KYMR returned +97.12% over the past 12 months, compared with -3.30% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kymera Therapeutics or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.80%, while Kymera Therapeutics does not currently pay a regular dividend.
Are Kymera Therapeutics and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.